Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update assessing carboplatin with or without nivolumab in metastatic triple-negative breast cancer. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC [Phase 2]
Phase 2 trial evaluating SBRT and oncolytic virus therapy prior to pembrolizumab in metastatic non-small cell lung cancer and metastatic tri…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update evaluating calorie restriction with or without metformin in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a multi-epitope folate receptor alpha peptide vaccine with GM-CSF and cyclophosphamide for treating triple…
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer [Phase 2]
Phase II study evaluating pembrolizumab with chemotherapy as neoadjuvant therapy for triple-negative breast cancer is ongoing with status no…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Neoadjuvant Carboplatin in Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update evaluating neoadjuvant carboplatin in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety trial of GEN1029 (HexaBody-DR5/DR5) in malignant solid tumors (termina ted; results posted in 2022).
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study on Androgen Receptor and Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update investigating androgen receptor targeted therapy in triple-negative breast cancer with androgen receptor positivity has…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer [Phase 2, Phase 3]
A trial update for a platinum and polyadenosine 5'-diphosphoribose polymerisation inhibitor in neoadjuvant treatment for triple-negative bre…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity [Phase 2]
Phase 2 trial investigating neoadjuvant docetaxel and carboplatin for anti-tumor activity in triple negative breast cancer; trial terminated…
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial [Phase 2]
Phase II randomized trial evaluating tucidinostat with metronomic capecitabine in metastatic triple-negative breast cancer; status and resul…
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer [Phase 2]
Phase 2 trial update studying neoadjuvant nab-paclitaxel in triple-negative or HER2-positive breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer [Phase 1, Phase 2]
A completed Phase 1/2 study evaluated neoadjuvant MEDI4736 (durvalumab) with weekly nab-paclitaxel and dose-dense AC in Stage I-III triple-n…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer [Phase 2, Phase 3]
Clinical trial update for neo-adjuvant chemotherapy in triple negative breast cancer spanning Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy [Phase 3]
Phase 3 clinical trial update on the use of platinum-based chemotherapy for residual triple-negative breast cancer after neoadjuvant therapy…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) [Phase 2]
Phase 2 trial evaluating CB-839 in combination with paclitaxel in participants with advanced triple negative breast cancer completed with re…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating eribulin mesylate combined with lobaplatin for recurrent or metastatic triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) [Phase 2]
Phase II multicenter trial evaluating durvalumab plus olaparib for platinum-treated advanced triple-negative breast cancer has completed wit…
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial comparing DCb (docetaxel/carboplatin) to EC-D (epirubicin/cyclophosphamide followed by docetaxel) as neoadjuvant chemotherapy …
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy [NA]
Clinical trial update for a breast cancer study using metabolic sodium MRI to assess early response to neoadjuvant chemotherapy; study termi…
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: FUSCC Refractory TNBC Umbrella (FUTURE) [Phase 1, Phase 2]
Clinical trial update for the FUTURE umbrella study in refractory triple-negative breast cancer spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating toripalimab in combination with chemotherapy after HIFU induction for early triple-negative breast cance…
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a single-dose cyclophosphamide plus pembrolizumab in metastatic triple negative breast cancer has complete…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) [Phase 2, Phase 3]
A phase 2/3 trial evaluating Eryaspase in combination with chemotherapy versus chemotherapy alone for triple negative breast cancer has been…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy [Phase 2]
Phase 2 trial evaluating gemcitabine plus cisplatin in triple negative breast cancer patients after neoadjuvant chemotherapy.